The Institute of Bioorganic Chemistry offers consumers a method of personalizing drug treatment in psychiatry using the results of pharmacogenetic testing as part of an outsourcing agreement is looking for partners to conclude a distribution service agreement.

The method of personalizing the treatment of mental and behavioral disorders using an automated information system for the clinical interpretation of the results of pharmacogenetic testing allows, based on the patient's genetic data, to sel ect the appropriate drug and its optimal dosage regimen (introduced into practical healthcare). The method is validated on the Belarusian population and is ethnospecific.

Correction of drug therapy based on genetic data contributed to a significant reduction in psychopathological symptoms, a decrease in hospitalization time, and an improvement in social functioning during follow-up in 80% of patients (50 patients with schizophrenia, schizotypal and delusional disorders). The average length of hospital stay per year (bed-days) in the study group decreased from 78.2 ± 13.2 to 28.9 ± 7.8 (p = 0.002 according to Wilcoxon's test). The economic effect fr om the introduction of the method was 2354.57 BYN per patient per year.

In comparison with analogues of pharmacogenetic tests for psychiatry Genomind (R) and GeneSight (R) (USA), the developed method is applicable for a complete list of psychotropic drugs registered in the Republic of Belarus and used for the correction and treatment of mental and behavioral disorders.

The information system for the interpretation of the results of pharmacogenetic testing of patients with mental and behavioral disorders "Pharmacogenetics" has been introduced and is actively used in the practical health care of the state institution "Republican Scientific and Practical Center for Mental Health".

A significant amount of fundamental research is carried out under the grants of the Belarusian Republican Foundation for Basic Research, including with the participation of international partners - organizations from Russia, the Czech Republic, etc.

Consumers of the method of personalizing drug treatment in psychiatry using the results of pharmacogenetic testing under an outsourcing agreement.
Partners for the conclusion of an agreement on distribution services.